To determine the contribution of KIR–HLA ligand interactions to the differential GBM killing efficacy in stem cell versus serum-containing medium, we genotyped the NK cells’ KIR receptors and their cognate HLA ligands on the GBM cells (Tables 2 and 3). Here, KIR3DL1 is linked to glioblastoma.